Epithelial Growth Factor Receptor Inhibitors for treatment of recurrent or progressive high grade glioma: an exploratory study - PubMed (original) (raw)

Clinical Trial

Epithelial Growth Factor Receptor Inhibitors for treatment of recurrent or progressive high grade glioma: an exploratory study

M Preusser et al. J Neurooncol. 2008 Sep.

Abstract

Introduction: Erlotinib and Gefitinib (EGFRi) are small molecules specifically inhibiting epidermal growth factor receptor (EGFR). We present here data of an exploratory study evaluating EGFRi monotherapy in patients with recurrent or progressive malignant glioma.

Patients: 21 patients with recurrent or progressive malignant glioma were included in this study. EGFRi treatment was started at a median of 1.8 years (range 0.54 to 10.95) after initial surgery. 20/21 patients had undergone radiotherapy and all patients had received at least one (range 1 to 5, median 2) line of systemic antineoplastic therapy. Patients received 100 or 150 mg Erlotinib or 250 mg Gefitinib orally per day.

Results: Median age at primary diagnosis was 47.9 years (range 31.9 to 76 years). 18 patients received a total of 92.8 months (median 3.03) of Erlotinib treatment and 3 patients received a total of 16.1 months (median 6.06) of Gefitinib treatment. The best responses were partial remission in one patient receiving Erlotinib and in two patients receiving Gefitinib, respectively. Median time to progression was 3.05 months. Six months after start of EGFRi treatment, 4/21 (19%) patients were progression-free and 6/21(29%) patients were alive. Expression of EGFRwt, EGFRvIII, PTEN, phospho-Akt or EGFRvIII/PTEN co-expression in tumor cells did not significantly associate with time to progression or survival time. In one patient EGFRi administration had to be discontinued due to toxicity (grade 3 rash).

Conclusion: EGFRi monotherapy is associated with therapeutic efficacy in only a small fraction of patients with malignant gliomas. Biomarkers reliably predicting tumor response to EGFRi need to be identified.

PubMed Disclaimer

Similar articles

• Phase II trials of erlotinib or gefitinib in patients with recurrent meningioma.
  Norden AD, Raizer JJ, Abrey LE, Lamborn KR, Lassman AB, Chang SM, Yung WK, Gilbert MR, Fine HA, Mehta M, Deangelis LM, Cloughesy TF, Robins HI, Aldape K, Dancey J, Prados MD, Lieberman F, Wen PY. Norden AD, et al. J Neurooncol. 2010 Jan;96(2):211-7. doi: 10.1007/s11060-009-9948-7. Epub 2009 Jun 28. J Neurooncol. 2010. PMID: 19562255 Free PMC article. Clinical Trial.
• Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas: North American Brain Tumor Consortium trial 04-02.
  Wen PY, Chang SM, Lamborn KR, Kuhn JG, Norden AD, Cloughesy TF, Robins HI, Lieberman FS, Gilbert MR, Mehta MP, Drappatz J, Groves MD, Santagata S, Ligon AH, Yung WK, Wright JJ, Dancey J, Aldape KD, Prados MD, Ligon KL. Wen PY, et al. Neuro Oncol. 2014 Apr;16(4):567-78. doi: 10.1093/neuonc/not247. Epub 2014 Jan 26. Neuro Oncol. 2014. PMID: 24470557 Free PMC article. Clinical Trial.
• Characterization and response of newly developed high-grade glioma cultures to the tyrosine kinase inhibitors, erlotinib, gefitinib and imatinib.
  Kinsella P, Howley R, Doolan P, Clarke C, Madden SF, Clynes M, Farrell M, Amberger-Murphy V. Kinsella P, et al. Exp Cell Res. 2012 Mar 10;318(5):641-52. doi: 10.1016/j.yexcr.2012.01.014. Epub 2012 Jan 20. Exp Cell Res. 2012. PMID: 22285130
• First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
  Greenhalgh J, Dwan K, Boland A, Bates V, Vecchio F, Dundar Y, Jain P, Green JA. Greenhalgh J, et al. Cochrane Database Syst Rev. 2016 May 25;(5):CD010383. doi: 10.1002/14651858.CD010383.pub2. Cochrane Database Syst Rev. 2016. PMID: 27223332 Updated. Review.
• Inhibition of the epidermal growth factor receptor in combined modality treatment for locally advanced non-small cell lung cancer.
  Ready N. Ready N. Semin Oncol. 2005 Apr;32(2 Suppl 3):S35-41. doi: 10.1053/j.seminoncol.2005.03.008. Semin Oncol. 2005. PMID: 16015534 Review.

Cited by

• Small molecule kinase inhibitors in glioblastoma: a systematic review of clinical studies.
  De Witt Hamer PC. De Witt Hamer PC. Neuro Oncol. 2010 Mar;12(3):304-16. doi: 10.1093/neuonc/nop068. Epub 2010 Feb 9. Neuro Oncol. 2010. PMID: 20167819 Free PMC article. Review.
• Experimental approaches for the treatment of malignant gliomas.
  Arko L, Katsyv I, Park GE, Luan WP, Park JK. Arko L, et al. Pharmacol Ther. 2010 Oct;128(1):1-36. doi: 10.1016/j.pharmthera.2010.04.015. Epub 2010 Jun 8. Pharmacol Ther. 2010. PMID: 20546782 Free PMC article. Review.
• Molecular diagnostics of gliomas: state of the art.
  Riemenschneider MJ, Jeuken JW, Wesseling P, Reifenberger G. Riemenschneider MJ, et al. Acta Neuropathol. 2010 Nov;120(5):567-84. doi: 10.1007/s00401-010-0736-4. Epub 2010 Aug 17. Acta Neuropathol. 2010. PMID: 20714900 Free PMC article. Review.
• Targeted therapy in the treatment of malignant gliomas.
  Lukas RV, Boire A, Nicholas MK. Lukas RV, et al. Onco Targets Ther. 2009 Feb 18;2:115-33. doi: 10.2147/ott.s3027. Onco Targets Ther. 2009. PMID: 20616900 Free PMC article.
• Prognostic significance of epidermal growth factor receptor expression in glioma patients.
  Li J, Liang R, Song C, Xiang Y, Liu Y. Li J, et al. Onco Targets Ther. 2018 Feb 7;11:731-742. doi: 10.2147/OTT.S155160. eCollection 2018. Onco Targets Ther. 2018. PMID: 29445288 Free PMC article.

References

1. 1. Oncologist. 2006 Feb;11(2):165-80 - PubMed
2. 1. Ann Oncol. 2007 Jun;18 Suppl 6:vi35-41 - PubMed
3. 1. Br J Cancer. 2007 Apr 10;96(7):1047-51 - PubMed
4. 1. Clin Cancer Res. 2004 May 1;10(9):3216-24 - PubMed
5. 1. Cancer Control. 2007 Jul;14(3):295-304 - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Ovid Technologies, Inc.
  • Springer

• Medical

  • MedlinePlus Health Information

• Research Materials

  • NCI CPTC Antibody Characterization Program

• Miscellaneous

  • NCI CPTAC Assay Portal